Fri, October 4, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. CNTA
Healthcare
Facebook Twitter Linkedin

Centessa Pharmaceuticals PLC ADR (NASDAQ:CNTA)

15.89 USD

-0.370 2.276%
Last Updated at: 2024-10-03T18:49:00Z

Centessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

44 203 9206789

https://www.centessa.com

Employees: 76

Key Executives

Sr. No. Name Title Year Born
1. Dr. Saurabh Saha M.D., Ph.D. CEO & Director 1977
2. Dr. Gregory M. Weinhoff M.B.A., M.D., MBA Principal Accounting Officer & CFO 1971
3. Dr. Antoine Yver M.D., M.Sc., MSc Exec. VP & Chairman of Devel. 1958
4. Dr. Thomas S. Templeman Ph.D. Chief Technology Officer 1960
5. Dr. David M. Chao Ph.D. Chief Admin. Officer 1968
6. Ms. Kristen K. Sheppard Esq., J.D. Sr. VP of Investor Relations & Corp. Communications NA
7. Mr. Iqbal J. Hussain L.L.B. Gen. Counsel, Chief Compliance Officer & Corp. Sec. 1981
8. Ms. Karen M. Anderson Chief People Officer 1967
9. Ms. Tia L. Bush Chief Quality Officer 1971
10. Dr. David John Grainger Ph.D. Chief Innovation Officer 1969

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.940 0.807% 116.24 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 0.000 0.000% 116.2 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 -9.265 2.005% 460 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 -24.030 2.310% 1037.5 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Income Before Tax -216.954M -380.957M -10.663M -5.061M
Minority Interest - - - -
Net Income -216.207M -381.071M -11.041M -5.284M
Selling General Administrative 55.2M 42.888M 1.139M 0.79M
Gross Profit - - - -
Reconciled Depreciation 0.131M - 0M 0.006M
Ebit -212.263M -379.785M -10.44M -5.053M
Ebitda -207.941M -379.751M -10.285M -4.937M
Depreciation And Amortization 4.322M 0.034M 0.155M 0.116M
Operating Income -212.263M -379.785M -10.44M -5.053M
Other Operating Expenses 210.283M 138.548M 10.44M 5.053M
Interest Expense 7.033M 1.172M 0.378M 0.118M
Tax Provision -0.747M - - -
Interest Income - - 0.254M 0.005M
Net Interest Income -7.033M - -0.378M -0.113M
Income Tax Expense -0.747M 0.114M 0.378M 0.223M
Total Revenue 0M - 0M 0M
Total Operating Expenses 210.283M 138.548M 10.44M 5.053M
Cost Of Revenue - - - -
Total Other Income Expense Net -4.691M -1.172M -0.223M -0.008M
Net Income From Continuing Ops -216.207M - -10.663M -5.061M
Net Income Applicable To Common Shares -216.207M -381.071M -10.663M -5.061M

Balance Sheet

(Currency in USD)
Breakdown 31-12-2023 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Total Assets 362.969M 444.307M 629.635M 11.717M 19.73M
Intangible Assets - - - - -
Other Current Assets 19.395M 3.271M 0.993M 0.006M 0.004M
Total Liab 126.725M 108.138M 138.081M 34.14M 6.066M
Total Stockholder Equity 236.244M 336.169M 491.554M -22.423M 13.664M
Other Current Liab 27.57M 24.502M 16.573M 0.922M -
Common Stock 0.273M 0.265M 0.252M 25.546M -
Capital Stock 0.273M 0.265M 0.252M 0M -
Retained Earnings -752.945M -601.86M -385.653M -22.423M -12.511M
Good Will - - - - -
Other Assets - 5.392M 0.699M 0.552M -
Cash 128.03M 393.644M 595.082M 7.227M -
Cash And Equivalents - - - - -
Total Current Liabilities 39.385M 38.338M 24.638M 8.619M 1.932M
Current Deferred Revenue - - - 1.038M -
Net Debt -43.442M -323.844M -519.382M -1.6M -
Short Term Debt - - - 5.627M 0.544M
Short Long Term Debt - - - 5.627M -
Short Long Term Debt Total 84.588M 69.8M 75.7M 5.627M 3.615M
Other Stockholder Equity 987.423M 939.261M 876.267M 0.572M 0.418M
Property Plant Equipment - 1.168M 0.162M - -
Total Current Assets 315.092M 393.644M 595.082M 11.165M 19.227M
Long Term Investments - - - - -
Short Term Investments 128.519M - - - -
Net Receivables 39.148M 26.723M 16.814M 2.931M -
Long Term Debt 75.7M 69.8M 75.7M - 3.615M
Inventory 0M -29.994M -17.807M 1.001M -
Accounts Payable 11.815M 13.836M 8.065M 1.032M -
Accumulated Other Comprehensive Income 1.493M -1.497M 0.688M - -
Non Currrent Assets Other 2.554M 49.495M 34.391M 0.552M -
Non Current Assets Total 47.877M 50.663M 34.553M 0.552M -
Capital Lease Obligations 8.888M - - - -
Long Term Debt Total - - - - -

Cash Flow

(Currency in USD)
Breakdown 31-12-2022 31-12-2021 31-12-2020 31-12-2019
Investments -0.931M - 0M 0M
Total Cashflows From Investing Activities -0.931M 63.256M 63.256M 63.256M
Total Cash From Financing Activities 0.457M 660.147M 1.362M 9.005M
Net Income -216.207M -381.071M -10.663M -5.061M
Change In Cash -201.438M 590.116M -9.343M 3.7M
Begin Period Cash Flow 595.082M 4.966M 16.57M 12.87M
End Period Cash Flow 393.644M 595.082M 7.227M 16.57M
Total Cash From Operating Activities -200.546M -135.109M -10.63M -5.825M
Depreciation 0.131M 0.034M 0.034M 0.006M
Other Cashflows From Investing Activities 0.206M 0.206M 0.206M 0.206M
Dividends Paid - - - -
Change To Inventory - - - -
Sale Purchase Of Stock - - 0.001M 5.174M
Other Cashflows From Financing Activities 0.457M 660.147M 1.362M 9.005M
Capital Expenditures 1.137M 0.186M 0.186M 0.186M
Change In Working Capital -2.831M 231.077M -0.489M -1.006M
Other Non Cash Items -3.747M 231.077M 0.186M -
Free Cash Flow -201.683M -135.295M -10.63M -5.825M

Funds

Sr. No. Name Purchased On Shares
1. Fidelity Select Biotechnology 6 months ago 2787194
2. T. Rowe Price Health Sciences 6 months ago 1479460
3. T. Rowe Price New Horizons 6 months ago 884299
4. US Small-Cap Growth II Equity Comp 6 months ago 884299
5. American Century Small Cap Growth Inv 6 months ago 810180
6. American Century U.S. Small Cap Growth 6 months ago 810180
7. Franklin Biotechnology Discv A(acc)USD 5 months ago 765214
8. Franklin Biotechnology Discovery A 5 months ago 391465
9. iShares Biotechnology ETF 5 months ago 347412
10. Heptagon Driehaus US Micro Cap Eq C$ Acc 6 months ago 334079
11. T. Rowe Price New Horizons Tr-Z 6 months ago 140249
12. Driehaus Micro Cap Growth USD 6 months ago 100805
13. TD Health Sciences - I 9 months ago 93155
14. Driehaus Micro Cap Growth USD 7 months ago 68789
15. T. Rowe Price Health Sciences Port 6 months ago 62892
16. Adara Smaller Companies 6 months ago 55745
17. Destinations Small-Mid Cap Equity I 5 months ago 53685
18. Fidelity Nasdaq Composite Index 6 months ago 33539
19. iShares Nasdaq US Biotech ETF USD Acc 5 months ago 30447
20. JHFunds2 Health Sciences NAV 6 months ago 27742

Institutions

Sr. No. Name Purchased On Shares
1. Medicxi Ventures Management (Jersey) Ltd 9 months ago 19963157
2. General Atlantic Llc 6 months ago 9681818
3. EcoR1 Capital, LLC 6 months ago 5618779
4. Vida Ventures Advisors, LLC 9 months ago 3931818
5. Perceptive Advisors LLC 6 months ago 3083307
6. First Light Asset Management, LLC 6 months ago 3002045
7. T. Rowe Price Associates, Inc. 6 months ago 2958079
8. FMR Inc 9 months ago 2787194
9. Adage Capital Partners Gp LLC 6 months ago 2250000
10. Octagon Capital Advisors LP 6 months ago 2060100
11. TCG Crossover Management, LLC 9 months ago 2040816
12. 5AM Venture Management, LLC 6 months ago 1245000
13. Morgan Stanley - Brokerage Accounts 9 months ago 1214050
14. Franklin Resources Inc 9 months ago 1115817
15. Driehaus Capital Management LLC 6 months ago 1104014
16. Artal Group S A 9 months ago 1012500
17. American Century Companies Inc 6 months ago 923120
18. Affinity Asset Advisors, LLC 9 months ago 795729
19. Tanager Wealth Management LLP 6 months ago 696096
20. Cormorant Asset Management, LLC 6 months ago 561600
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App